^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    JAK1 inhibitor

    Related drugs:
    1d
    Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov)
    P3, N=110, Recruiting, AbbVie | Trial primary completion date: Jun 2027 --> Feb 2031
    Trial primary completion date
    2d
    APHP220916: JAK1 inhibitor treatment of inflammatory liver adenomas (2023-505278-13-00)
    P1/2, N=50, Active, not recruiting, Assistance Publique Hopitaux De Paris | Recruiting --> Active, not recruiting
    Enrollment closed
    4d
    Single-Cell Computational Frameworks for Quantifying BET Bromodomain Inhibitor Resistance and Screening Re-Sensitizer Drugs in Triple-Negative Breast Cancer. (PubMed, Adv Sci (Weinh))
    Furthermore, in vitro and in vivo experiments validate the ability of the small molecule filgotinib, identified by D-FR20, to re-sensitize BBDI and effectively eliminate resistant TNBC cells. Collectively, this study provides two computational frameworks for predicting BBDI resistance and candidate re-sensitizer, as well as demonstrates the roles of ferroptosis in BBDI resistance, offering a promising avenue for TNBC treatment.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4)
    4d
    CD: TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response (clinicaltrials.gov)
    P4, N=312, Recruiting, Sixth Affiliated Hospital, Sun Yat-sen University
    New P4 trial
    |
    CRP (C-reactive protein)
    4d
    UP-SPOUT: A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis (clinicaltrials.gov)
    P4, N=100, Recruiting, CARE ARTHRITIS LTD. | Trial completion date: Dec 2026 --> Oct 2028 | Trial primary completion date: Dec 2026 --> Sep 2028
    Trial completion date • Trial primary completion date
    4d
    A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus (clinicaltrials.gov)
    P2, N=198, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P2 trial
    5d
    Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Novartis Pharmaceuticals | Trial primary completion date: Nov 2027 --> Nov 2026
    Trial primary completion date
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    6d
    IFNγ-induced antigen loss in chimeric antigen receptor-T cell therapy. (PubMed, Front Immunol)
    This mechanism of antigen loss can be rescued with anti-IFNγ neutralizing antibody, the JAK inhibitor ruxolitinib, or 4-phenylbutyrate (an ER stress reliever). We revealed a negative effect of IFNγ that uniquely interferes with immunotherapies targeting native surface antigens, such as CART and BiTE therapies, which may be reversed by disrupting stress signaling pathways to enhance solid tumor CART and BiTE immunotherapies.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • GUCY2C (Guanylate Cyclase 2C)
    |
    Jakafi (ruxolitinib)
    6d
    Filgotinib inhibits METTL3-mediated m6A of EIF3A by targeting ERG-TBP to suppress PDAC progression JAK-STAT3-independently. (PubMed, NPJ Precis Oncol)
    In contrast, other JAK-STAT3 inhibitors such as ruxolitinib and knockdown of STAT3 does not replicate this effect, indicating that the anti-tumor effect of filgotinib is independent of JAK-STAT3 signaling. This study offers innovative insights and potential therapeutic strategies for the treatment of PDAC through EIF3A m6A.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • EIF6 (Eukaryotic Translation Initiation Factor 6) • METTL3 (Methyltransferase Like 3)
    |
    Jakafi (ruxolitinib)
    6d
    Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    carboplatin • paclitaxel • AiRuiKa (camrelizumab) • AiSuDa (ivarmacitinib)
    6d
    A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) (clinicaltrials.gov)
    P3, N=330, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting
    Enrollment closed
    6d
    cHL-PG01: A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL) (2024-520123-83-01)
    P1/2, N=48, Active, not recruiting, Universita' Degli Studi Di Perugia | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    Keytruda (pembrolizumab) • Jakafi (ruxolitinib) • Adcetris (brentuximab vedotin)